



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Antivirals - Cytomegalovirus (CMV)

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Form with fields: Patient Name, Prescriber Name, HPP Member Number, Date of Birth, Patient Primary Phone, Address, City, State ZIP, Line of Business, Drug Name, Quantity, Directions, Diagnosis Code, Diagnosis, etc.

HPP's maximum approval time is 12 months but may be less depending on the drug.

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Questions Q1-Q7 regarding drug use, patient age, specialist consultation, stem cell transplant, CMV seropositivity, and CMV reactivation risk.

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above.



HEALTH PARTNERS PLANS  
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Antivirals - Cytomegalovirus (CMV)

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.**

Patient Name:	Prescriber Name:
---------------	------------------

<p>Q8. Will the patient initiate treatment with Prevmis (letermovir) or has the patient initiated treatment with Prevmis (letermovir) between day 0 and day 28 post-transplantation?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q9. Does the patient have evidence of cytomegalovirus (CMV) replication, as demonstrated by antigenemia or polymerase chain reaction (PCR)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q10. Is this a request for maribavir?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q11. Is maribavir being prescribed by or in consultation with an appropriate specialist (i.e., hematologist/oncologist, infectious disease specialist, or transplant specialist)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q12. Is there notes showing what maribavir is being used to treat?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q13. Is prescribed maribavir for continuation of treatment upon inpatient discharge?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q14. Does the patient history of therapeutic failure of or a contraindication or an intolerance to at least one of the following (Ganciclovir, Valganciclovir, Cidofovir, Foscarnet)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q15. Does the patient have culture and sensitivity results documenting that only maribavir will be effective?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q16. Does the patient have a documented history of therapeutic failure, contraindication to, or intolerance of the preferred cytomegalovirus (CMV) antiviral drugs for the patient's diagnosis or indication (e.g., Prevmis, Valcyte oral solution, valganciclovir tablet)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q17. Is the beneficiary's infection not susceptible to the preferred Antivirals, CMV?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q18. Is the beneficiary's infection susceptible to the requested non-preferred Antiviral, CMV?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q19. Additional Information:</p>

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



Health Partners Plans

HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Antivirals - Cytomegalovirus (CMV)

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Form with fields for Patient Name and Prescriber Name

Empty rectangular box for additional information

Prescriber Signature

Date

Updated for 2023